Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: Cynic 2005 who wrote (414)	7/28/1998 5:47:00 PM
From: yard_man	Read Replies (1) \| Respond to of 798

No, I think that was the other stent. There were two that were awaiting approval. Long term debt increased quite a bit. They never did release how much they paid for that recent acquisition. I guess that must be it. Don't get me wrong, I think the stock is overpriced. IMO, there is going to be more competition in the stents than analysts are thinking, but earnings weren't a disaster without their new one, just nothing to write home about. Next quarter, if they don't clean up and show some real growth, bottom and top line, it'll be back down in the 50's even if this silly BULL market stays afloat. I don't expect any more downgrades at this point.